SCHEDULE 13D/A 0001415889-25-001009 0002050755 XXXXXXXX LIVE 3 Common Stock, par value $.0001 per share 09/11/2025 false 0001817229 929033108 VOR BIOPHARMA INC.

100 Cambridgepark Drive, Suite 101 Cambridge MA 02140

Frank Huang, Manager (415) 541-0200 101 Mission Street, Suite 1000 San Francisco CA 94105 0002050755 N Reprogrammed Interchange LLC WC N CA 0.00 33928487.00 0.00 33928487.00 33928487.00 N 26.8 OO 0001519339 N Reid Hoffman AF N X1 0.00 33928487.00 0.00 33928487.00 33928487.00 N 26.8 IN Common Stock, par value $.0001 per share VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge MA 02140 This Amendment No. 3 to Schedule 13D amends and supplements the information provided in the previously filed Statement on Schedule 13D filed with the Securities and Exchange Commission on January 7, 2025 and in Amendment No. 1 and Amendment No. 2 thereto filed with the Securities and Exchange Commission on August 29, 2025 and September 9, 2025, respectively (collectively, the "Schedule 13D"), jointly on behalf of Reprogrammed Interchange LLC and Reid Hoffman (each a "Reporting Person" and collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain unchanged in all material respects and in full force and effect. Capitalized terms used but not defined herein have the meaning ascribed to such term in the Schedule 13D, as amended. Responses to each item of this Amendment No. 3 to Schedule 13D are incorporated by reference into the response to each other item, as applicable. Not applicable. Item 4 of Schedule 13D is hereby amended and supplemented as follows: From September 8, 2025 through September 11, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outstanding shares of Common Stock of the Issuer: 1. 464,421 shares on September 8, 2025, at a weighted average per share sale price of $1.9897. 2. 449,226 shares on September 9, 2025, at a weighted average per share sale price of $2.0004. 3. 350,000 shares on September 10, 2025, at a weighted average per share sale price of $1.8151. 4. 284,805 shares on September 11, 2025, at a weighted average per share sale price of $1.8308. The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Amendment No. 3 to the Schedule 13D, and the information set forth or incorporated in Items 2, 3, 4, 6 and 7, is incorporated by reference in its entirety into this Item 5. Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets, (ii) shared power to vote or to direct the vote: See line 8 of cover sheets, (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets, and (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets. During the past 60 days, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions: 1. 387,346 shares on August 25, 2025, at a weighted average per share sale price of $2.1163. 2. 284,190 shares on August 26, 2025, at a weighted average per share sale price of $2.0808. 3. 611,647 shares on August 27, 2025, at a weighted average per share sale price of $2.0053. 4. 806,351 shares on August 28, 2025, at a weighted average per share sale price of $2.0115. 5. 554,612 shares on September 3, 2025, at a weighted average per share sale price of $1.9961. 6. 453,016 shares on September 4, 2025, at a weighted average per share sale price of $1.9285. 7. 400,000 shares on September 5, 2025, at a weighted average per share sale price of $1.9682. Not applicable. Not applicable. Not applicable. Reprogrammed Interchange LLC /s/ Frank Huang 09/12/2025 Reid Hoffman /s/ Reid Hoffman 09/12/2025